%0 Journal Article
%T The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects
%A Eric Derom
%A Guy F. Joos
%A Guy G. Brusselle
%J Archive of "Therapeutic Advances in Respiratory Disease".
%D 2019
%R 10.1177/1753466619843426
%X Long-acting bronchodilators are the cornerstone of pharmacologic treatment of chronic obstructive pulmonary disease (COPD). Spiolto£¿ or Stiolto£¿ is a fixed-dose combination (FDC) containing two long-acting bronchodilators, the long-acting muscarinic receptor antagonist tiotropium (TIO) and the long-acting ¦Â2-adrenoceptor agonist olodaterol (OLO), formulated in the Respimat£¿ Soft Mist£¿ inhaler. A total of 13 large, multicentre studies of up to 52£¿weeks¡¯ duration have documented its efficacy in more than 15,000 patients with COPD. TIO/OLO 5/5£¿¦Ìg FDC significantly increases pulmonary function compared with placebo and its respective constituent mono-components TIO 5£¿¦Ìg and OLO 5£¿¦Ìg. TIO/OLO 5/5£¿¦Ìg also results in statistically and clinically significant improvements in patient-reported outcomes, such as dyspnoea, use of rescue medication, and health status. Addition of OLO 5£¿¦Ìg to TIO 5£¿¦Ìg reduces the rate of moderate-to-severe exacerbations by approximately 10%. Compared with placebo and TIO 5£¿¦Ìg, TIO/OLO 5/5£¿¦Ìg significantly improves exercise capacity (e.g. endurance time) and physical activity, the latter increase being reached by a unique combination behavioural modification intervention, dual bronchodilatation and exercise training. Overall, the likelihood for patients to experience a clinically significant benefit is higher with TIO/OLO 5/5£¿¦Ìg than with its constituent mono-components, which usually yield smaller improvements which do not always reach statistical significance, compared with baseline or placebo. This supports the early introduction of TIO/OLO 5/5£¿¦Ìg in the management of patients with symptomatic COPD
%K bronchodilatation
%K COPD
%K dyspnoea
%K exacerbation
%K exercise tolerance
%K hyperinflation
%K inspiratory capacity
%K LABA
%K LAMA
%K physical activity
%K spirometry
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475840/